: AstraZeneca’s preventive COVID therapy no longer effective against current variants


AstraZeneca AZN, -0.96% AZN, -1.54% said Thursday that the Food and Drug Administration is no longer allowing healthcare providers to prescribe Evusheld, a therapy authorized for pre-exposure prophylaxis of COVID-19, citing its lack of effectiveness against the currently circulating variants. The company said Evusheld does not neutralize subvariants like XBB.1.5, BQ.1, and BQ.1.1 — the three most common strains of the virus circulating in the U.S., according to the Centers for Disease Control and Prevention. Evusheld is authorized to prevent COVID infections in people who are severely immunocompromised.U.S.-listed shares of AstraZeneca are up 15.1% over the past year, while the S&P 500 SPX, +1.10% has declined 6.2%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleThe Margin: That delivery worker who interrupted a college basketball game? It was just a prank.
Next articleU.S. new-home sales rise despite broader weakness in real-estate sector


Please enter your comment!
Please enter your name here